PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

Detalles Bibliográficos
Autores principales: Sharp, A., Williams, A., Blagden, S., Plummer, R., Hochhauser, D., Krebs, M. G., Pacey, S., Evans, J., Whelan, S., Nandakumar, S., Rogers, S., Jameson, K. L., Basile, F. G., de Bono, J., Arkenau, H.-T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431483/
http://dx.doi.org/10.1097/01.HS9.0000851228.41662.2b

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431483/
http://dx.doi.org/10.1097/01.HS9.0000851228.41662.2b

Ejemplares similares